Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma

Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma

Abstract Background There is a lack of effective treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Furthermore, the response rate of NPC patients to programmed death 1 (PD-1) inhibitors is approximately 20% to 30%. Thus, we aimed to explore reliable and minimally invasive pro...

Full description

Bibliographic Details
Main Authors: Ao Zhang, Guanqing Zhong, Luocan Wang, Rongzeng Cai, Runkun Han, Caixia Xu, Shulin Chen, Peng Sun, Hao Chen
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Cancer Cell International
Subjects:
Biomarker
PD-1
Nasopharyngeal carcinoma
ICB
Dynamic monitor
Online Access:https://doi.org/10.1186/s12935-021-02217-y

Internet

https://doi.org/10.1186/s12935-021-02217-y

Similar Items